Pediatrics – Allergy and Immunology | Page 2 of 3 | Links Medicus Content Curation & Alerts in Medicine

Joint consensus guidelines on the diagnosis and management of eosinophilic esophagitis in children and adults.

25 May, 2022 | 11:32h | UTC

British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults – Gut

Guideline: Contact dermatitis.

10 May, 2022 | 10:54h | UTC

German S1 guideline: Contact dermatitis – Journal of the German Society of Dermatology

Analysis of an intervention for emergency medical services personnel to reduce epinephrine dosing errors in infants.

19 Apr, 2022 | 01:52h | UTC

Analysis of an Intervention for Emergency Medical Services Personnel to Reduce Epinephrine Dosing Errors in Infants – JAMA Network Open

Commentary on Twitter

In this QI study, an infant resuscitation simulation intervention using 1mL syringes to draw up epinephrine (vs dosing from prefilled 10mL syringes) was associated with increased appropriate epinephrine use & fewer dosage errors, in less time. https://t.co/M3ztB1LMDi

— JAMA Network Open (@JAMANetworkOpen) April 15, 2022

Cohort Study: Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection.

12 Apr, 2022 | 09:57h | UTC

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study – Canadian Medical Association Journal

News Release: Children older than 5 at higher risk of COVID-19-related multisystem inflammatory syndrome – Canadian Medical Association Journal

Commentary: Older Kids More Vulnerable to MIS-C: Study – HealthDay

Translating research into practice: What’s new in the 2021 EAACI food allergy prevention guidelines?

8 Apr, 2022 | 10:00h | UTC

Translating research into practice: What’s new in the 2021 EAACI food allergy prevention guidelines? – Clinical & Experimental Allergy

Original Guideline: EAACI guideline: Preventing the development of food allergy in infants and young children – Pediatric Allergy and Immunology

Practice Guideline: Prevention and management of allergic reactions to food in child care centers and schools

Study: Early Introduction of Allergenic Foods Can Prevent Food Allergies in High Risk Infants

AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease

Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society (free)

Short Review: Food Allergy Prevention with Early Food Introduction

Cohort Study: Short-term outcomes of corticosteroid monotherapy in multisystem inflammatory syndrome in children.

30 Mar, 2022 | 10:40h | UTC

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

Commentary on Twitter

In this study, corticosteroid monotherapy successfully treated a subset of patients with mild multisystem inflammatory syndrome in children. https://t.co/fuhHeBSaRp

— JAMA Pediatrics (@JAMAPediatrics) March 28, 2022

Cohort Study: Prenatal occupational disinfectant exposure linked to increased risk of childhood allergies.

30 Mar, 2022 | 08:48h | UTC

Prenatal occupational disinfectant exposure and childhood allergies: the Japan Environment and Children’s study – Occupational & Environmental Medicine

Commentary: Disinfectant use by pregnant women may increase risk for asthma and eczema in children – BMJ/News Medical

Commentary on Twitter

Disinfectant use during pregnancy linked to childhood asthma and eczema, suggests @OEM_BMJ research https://t.co/90JYoTFHpo pic.twitter.com/zlqouZWQSM

— BMJ Group (@bmj_company) March 29, 2022

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

28 Mar, 2022 | 09:48h | UTC

Factors Associated With Penicillin Allergy Labels in Electronic Health Records of Children in 2 Large US Pediatric Primary Care Networks – JAMA Network Open

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Consensus Recommendations: Management of a Surgical Patient with a Label of Penicillin Allergy

Practical Guide for Pharmacists to Successfully Implement Penicillin Allergy Skin Testing

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

Commentary on Twitter

In this cohort study of more than 330,000 children, less than 5% were labeled with penicillin allergy with wide variation across practices, with 8% of those labeled despite not receiving any penicillin prescription. https://t.co/kvXcm1RKRd

— JAMA Network Open (@JAMANetworkOpen) March 15, 2022

Food protein-induced enterocolitis syndrome: A large French multicentric experience.

25 Mar, 2022 | 08:27h | UTC

Food protein-induced enterocolitis syndrome: A large French multicentric experience – Clinical and Translational Allergy

Systematic Review: Strategies for using topical corticosteroids in children and adults with eczema.

21 Mar, 2022 | 08:33h | UTC

Strategies for using topical corticosteroids in children and adults with eczema – Cochrane Library

Summary: What is the best way to use topical corticosteroids to treat people with eczema? – Cochrane Library

Commentary on Twitter

https://twitter.com/CochraneUK/status/1504548242738102273

Retrospective Cohort: Asthma in children and adolescents is not associated with increased risk of SARS-CoV-2 infection.

15 Mar, 2022 | 08:55h | UTC

Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents – Pediatrics

Commentary: Kids with asthma not at higher risk of COVID-19, study finds – CIDRAP

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break.

M-A: Asthma does not increase the risk of infection, hospitalization, ICU admission, and mortality from COVID-19

Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death

Asthma in COVID-19 hospitalizations: An overestimated risk factor?

Open Label RCT: Azithromycin for poorly controlled asthma in children.

15 Mar, 2022 | 08:39h | UTC

Azithromycin for Poorly Controlled Asthma in Children: A randomized controlled trial – CHEST (link to abstract – $ for full-text)

Commentary: Adding azithromycin to standard care improves asthma control, exacerbations in children – Healio

Systematic Review: Effect of asthma education on health outcomes in children.

25 Feb, 2022 | 11:09h | UTC

Effect of asthma education on health outcomes in children: a systematic review – Archives of Disease in Childhood

Anti-inflammatory treatment of Kawasaki Disease: comparison of current guidelines and perspectives.

25 Feb, 2022 | 10:29h | UTC

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

ACR Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19.

15 Feb, 2022 | 10:17h | UTC

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3 – Arthritis & Rheumatism

Commentary and summary: ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID – RheumNow

Clinical practice guideline on tympanostomy tubes in children.

10 Feb, 2022 | 10:10h | UTC

Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update) – Otolaryngology–Head and Neck Surgery

Short Review | Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2.

2 Feb, 2022 | 08:13h | UTC

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Commentary: Vaccine hypersensitivity in children – News Medical

RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.

24 Jan, 2022 | 08:18h | UTC

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases

Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay

In a study with 1110 children with prolonged fever, MRP8/14 serum levels were validated as a diagnostic marker for systemic juvenile idiopathic arthritis.

14 Jan, 2022 | 08:07h | UTC

MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link to abstract – $ for full-text)

Commentary: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology

RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.

9 Dec, 2021 | 10:21h | UTC

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.

19 Nov, 2021 | 10:34h | UTC

Biologics for Asthma and Allergic Skin Diseases in Children – Pediatrics

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

4 Nov, 2021 | 10:00h | UTC

Ten Things to Know About MIS-C – American College of Cardiology

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

Podcast: Atopic Dermatitis Pearls.

27 Oct, 2021 | 01:01h | UTC

Atopic Dermatitis Pearls – The Cribsiders

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

12 Sep, 2021 | 21:54h | UTC

One-Year Outcomes of Critical Care Patients Post–COVID-19 Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

Commentary: Outcome Good at One Year for Majority of PIMS-TS Patients – HealthDay

Commentary on Twitter

A new study reports that a small number of pediatric patients are at risk for poor long-term outcomes of multisystem inflammatory syndrome in children. https://t.co/rUk4YEGRin pic.twitter.com/CgBi33Mzd5

— JAMA Pediatrics (@JAMAPediatrics) September 2, 2021

Stay Updated in Your Specialty